(61 days)
Not Found
No
The description details a standard in vitro diagnostic assay based on light scattering measurements, with no mention of AI or ML technologies.
No.
This device is an in vitro diagnostic assay used for the quantitative determination of rheumatoid factor to aid in the diagnosis of rheumatoid arthritis, not for treating or preventing a disease.
Yes
The "Intended Use / Indications for Use" section explicitly states that the "Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis," indicating its role in assisting with a diagnosis.
No
The device description clearly states it is an "in vitro diagnostic assay" that involves chemical reactions and light scattering measurements, indicating it is a physical reagent and not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the assay is used for the quantitation of rheumatoid factor in human serum or plasma and "may aid in the diagnosis of rheumatoid arthritis." This indicates it's used to analyze samples taken from the human body to provide information for diagnostic purposes.
- Device Description: The "Device Description" further clarifies that it's an "in vitro diagnostic assay" and describes how it interacts with components in the human sample (rheumatoid factor in the sample interacts with aggregated human gamma globulin in the reagent).
- Performance Studies: The performance studies describe testing the assay's performance using control material and comparing it to a predicate device, which is typical for IVD submissions.
The definition of an In Vitro Diagnostic (IVD) is a medical device that is used to examine specimens, such as blood, urine, or tissue, that have been taken from the human body to detect diseases, conditions, or infections. This description perfectly aligns with the information provided about this Rheumatoid Factor assay.
N/A
Intended Use / Indications for Use
The Rheumatoid Factor assay is used for the quantitation of rheumatoid factor (antibodies to immunoglobulins) in human serum or plasma. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.
Product codes (comma separated list FDA assigned to the subject device)
DHR
Device Description
Rheumatoid Factor is an in vitro diagnostic assay for the quantitative determination of rheumatoid factor in human serum or plasma. The rheumatoid factor, an autoimmune antibody, in the sample interacts with the aggregated (denatured) human gamma globulin in the reagent forming immune complexes. The immune complexes cause an increase in light scattering, measured at 340 and 700 nm, which correlates with the concentration of rheumatoid factor in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies were conducted using the AEROSET™ System. The Rheumatoid Factor assay method comparison yielded acceptable correlation with the K-ASSAY Rheumatoid Factor assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9883, slope = 1.082, and the Y-intercept = -3.168 U/mL. Precision studies were conducted using the Rheumatoid Factor assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 502 is 5.2% and Level 2/Panel 503 is 2.2%. The Rheumatoid Factor assay range is 0.76 to 413.08 U/mL. The limit of quantitation (sensitivity) of the Rheumatoid Factor assay is 2.97 U/mL. These data demonstrate that the performance of the Rheumatoid Factor assay is substantially equivalent to the performance of the K-ASSAY Rheumatoid Factor assay on the Hitachi 717 Analyzer.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
correlation coefficient = 0.9883, slope = 1.082, and the Y-intercept = -3.168 U/mL. The total %CV for Level 1/Panel 502 is 5.2% and Level 2/Panel 503 is 2.2%. The Rheumatoid Factor assay range is 0.76 to 413.08 U/mL. The limit of quantitation (sensitivity) of the Rheumatoid Factor assay is 2.97 U/mL.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5775 Rheumatoid factor immunological test system.
(a)
Identification. A rheumatoid factor immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the rheumatoid factor (antibodies to immunoglobulins) in serum, other body fluids, and tissues. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.(b)
Classification. Class II (performance standards).
0
510(k) Summary
| Submitter's Name/Address | Abbott Laboratories |
|---|---|
| 1920 Hurd Drive | |
| Irving, Texas 75038 |
| Contact Person | Mark Littlefield |
|---|---|
| Section Manager MS 1-8 | |
| ADD Regulatory Affairs | |
| (972) 518-6062 | |
| Fax (972) 753-3367 |
| Date of Preparation of this Summary: | January 4, 1999 |
|---|---|
| Device Trade or Proprietary Name: | RF |
| Device Common/Usual Name or Classification Name: | Rheumatoid Factor |
| Classification Number/Class: | Class II |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K090635
Test Description:
Rheumatoid Factor is an in vitro diagnostic assay for the quantitative determination of rheumatoid factor in human serum or plasma. The rheumatoid factor, an autoimmune antibody, in the sample interacts with the aggregated (denatured) human gamma globulin in the reagent forming immune complexes. The immune complexes cause an increase in light scattering, measured at 340 and 700 nm, which correlates with the concentration of rheumatoid factor in the sample.
Rheumatoid Factor 510(k) January 4, 1999
Rf_5_VI.lwp
Section II Page I
Image /page/0/Picture/9 description: The image shows a sequence of numbers. The sequence consists of five zeros followed by two ones. The numbers are printed in a bold, sans-serif font.
1
Substantial Equivalence:
The Rheumatoid Factor assay is substantially equivalent to the K-ASSAY® Rheumatoid Factor assay (K964415) on the Hitachi® 717 Analyzer.
Both assays vield similar Performance Characteristics. Similarities:
- Both assays are in vitro immunoassays. t the state the state the state the state the state the station of the firm and the firm and the finitial was and the finitial was and the finitial was and the finalistic the
- Both assays can be used for the quantitative determination of rheumatoid . factor.
- Both assays yield similar clinical results. .
- Both assays are based on the light scattering properties of immune complexes. .
Differences:
- There is a difference between the assay range. .
- There is a difference in the test mode. .
Intended Use:
The Rheumatoid Factor assay is used for the quantitation of rheumatoid factor in human serum or plasma.
Performance Characteristics:
Comparative performance studies were conducted using the AEROSET™ System. The Rheumatoid Factor assay method comparison yielded acceptable correlation with the K-ASSAY Rheumatoid Factor assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9883, slope = 1.082, and the Y-intercept = -3.168 U/mL. Precision studies were conducted using the Rheumatoid Factor assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 502 is 5.2% and Level 2/Panel 503 is 2.2%. The Rheumatoid Factor assay range is 0.76 to 413.08 U/mL. The limit of quantitation (sensitivity) of the Rheumatoid Factor assay is 2.97 U/mL. These data demonstrate
Rheumatoid Factor 510(k) January 4, 1999 Rf_5_VI.lwp
Section II Page 2
0000012
2
that the performance of the Rheumatoid Factor assay is substantially equivalent to the performance of the K-ASSAY Rheumatoid Factor assay on the Hitachi 717 Analyzer.
Conclusion:
The Rheumatoid Factor assay is substantially equivalent to the K-ASSAY Rheumatoid Factor assay on the Hitachi 717 Analyzer as demonstrated by results obtained in the studies.
Rheumatoid Factor 510(k) January 4, 1999 Rf_5_V1.lwp
Section II Page 3
Image /page/2/Picture/5 description: The image shows the number 0000013 in a bold, sans-serif font. The numbers are black against a white background. The number is likely part of a sequence or identification code.
3
Image /page/3/Picture/1 description: The image shows the logo for the United States Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is an abstract image of an eagle or bird-like figure with three stylized lines representing its wings or feathers.
Public Health Service
MAR - 8 1999
Mr. Mark Littlefield Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
Re: K990035 Trade Name: RF Regulatory Class: II Product Code: DHR Dated: January 4, 1999 Received: January 6, 1999
Dear Mr. Littlefield:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours.
Steven Autman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Rheumatoid Factor Device Name:
Indications For Use:
The Rheumatoid Factor assay is used for the quantitation of rheumatoid factor (antibodies to immunoglobulins) in human serum or plasma. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.
Peter E. Malin
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use V OR Over-The-Counter Use (Per 21 CFR 801.109)
(Optional Format 1-2-96)
Rheumatoid Factor 510(k) January 4, 1999 Rf_5_VI.lwp